Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535182 · ClinicalTrials.gov registry record
Pilot Study Using Propranolol To Promote Prenylation Of Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients
A clinical trial, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- 25
- Enrollment target
NCT02535182: Completed study, sponsored by Medical College of Wisconsin.
NCT02535182 is a clinical trial that has completed, run by Medical College of Wisconsin. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02535182 has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This is a an ancillary study designed to explore whether an additional cell signaling pathway (prenylation of Rap1) that was recently identified as being under beta-adrenergic control may be affected by beta-blocker use.
Primary Outcome
Level of prenylation will be compared between patients exposed vs. not exposed to propranolol from 1-3 weeks before to 4 weeks following transplantation.
Interventions
- OTHER Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-08 |
| Est. Completion | 2020-02 |
What the finished NCT02535182 record still lists
NCT02535182 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Draw is the first listed.
NCT02535182 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02535182 about?
NCT02535182 is a clinical study titled "Pilot Study Using Propranolol To Promote Prenylation Of Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients". This is a an ancillary study designed to explore whether an additional cell signaling pathway (prenylation of Rap1) that was recently identified as being under beta-adrenergic control may be affected by beta-blocker use.
What is the current status of trial NCT02535182?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2015-08. Estimated completion is 2020-02.
What interventions are being tested in trial NCT02535182?
The interventions under investigation include: Blood Draw (OTHER).
Who is sponsoring clinical trial NCT02535182?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia